{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T20:48:43Z","timestamp":1779137323842,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T00:00:00Z","timestamp":1548806400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5314-0","type":"journal-article","created":{"date-parts":[[2019,1,30]],"date-time":"2019-01-30T13:03:43Z","timestamp":1548853423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0447-3206","authenticated-orcid":false,"given":"Sabrina","family":"Borchert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wessolly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Schmeller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Mairinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Kollmeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Mairinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Herold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel C.","family":"Christoph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F. H.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfried E. E.","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Till","family":"Pl\u00f6nes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremias","family":"Wohlschlaeger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kurt Werner","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian D.","family":"Mairinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,30]]},"reference":[{"issue":"11","key":"5314_CR1","doi-asserted-by":"publisher","first-page":"238","DOI":"10.21037\/atm.2017.04.29","volume":"5","author":"M Carbone","year":"2017","unstructured":"Carbone M, Yang H. Mesothelioma: recent highlights. Ann Transl Med. 2017;5(11):238.","journal-title":"Ann Transl Med"},{"issue":"6","key":"5314_CR2","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00428-017-2133-z","volume":"470","author":"FD Mairinger","year":"2017","unstructured":"Mairinger FD, Werner R, Flom E, Schmeller J, Borchert S, Wessolly M, et al. miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma. Virchows Arch. 2017;470(6):627\u201337.","journal-title":"Virchows Arch"},{"issue":"2","key":"5314_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.5114\/pjp.2016.61445","volume":"67","author":"G Turkcu","year":"2016","unstructured":"Turkcu G, AlabalIk U, Keles AN, Ibiloglu I, Kucukoner M, Sen HS, et al. Comparison of SKIP expression in malignant pleural mesotheliomas with Ki-67 proliferation index and prognostic parameters. Pol J Pathol. 2016;67(2):108\u201313.","journal-title":"Pol J Pathol"},{"issue":"1","key":"5314_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ijc.23874","volume":"124","author":"F Montanaro","year":"2009","unstructured":"Montanaro F, Rosato R, Gangemi M, Roberti S, Ricceri F, Merler E, et al. Survival of pleural malignant mesothelioma in Italy: a population-based study. Int J Cancer. 2009;124(1):201\u20137.","journal-title":"Int J Cancer"},{"issue":"2","key":"5314_CR5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ejcts.2007.09.044","volume":"33","author":"P Borasio","year":"2008","unstructured":"Borasio P, Berruti A, Bille A, Lausi P, Levra MG, Giardino R, et al. Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients. Eur J Cardiothorac Surg. 2008;33(2):307\u201313.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"2","key":"5314_CR6","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/CCO.0000000000000053","volume":"26","author":"DC Christoph","year":"2014","unstructured":"Christoph DC, Eberhardt WE. Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements. Curr Opin Oncol. 2014;26(2):171\u201381.","journal-title":"Curr Opin Oncol"},{"issue":"9","key":"5314_CR7","first-page":"3553","volume":"33","author":"CC Boons","year":"2013","unstructured":"Boons CC, MW VANT, Burgers JA, Beckeringh JJ, Wagner C, Hugtenburg JG. The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review. Anticancer Res. 2013;33(9):3553\u201361.","journal-title":"Anticancer Res"},{"issue":"9","key":"5314_CR8","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1097\/JTO.0b013e318260deaa","volume":"7","author":"DC Christoph","year":"2012","unstructured":"Christoph DC, Asuncion BR, Mascaux C, Tran C, Lu X, Wynes MW, et al. Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma. J Thorac Oncol. 2012;7(9):1440\u20138.","journal-title":"J Thorac Oncol"},{"key":"5314_CR9","volume-title":"Molecular biological analysis of malignant pleural mesothelioma [dissertation]","author":"RF Walter","year":"2014","unstructured":"Walter RF. Molecular biological analysis of malignant pleural mesothelioma [dissertation]. Essen: Ruhrlandklinik, west German lung Centre, At the university hospital Essen \u2013 university hospital: university Duisburg-Essen; 2014."},{"issue":"2","key":"5314_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrc.2015.21","volume":"16","author":"CJ Lord","year":"2016","unstructured":"Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016;16(2):110\u201320.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"5314_CR11","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00280-017-3401-y","volume":"80","author":"G Srinivasan","year":"2017","unstructured":"Srinivasan G, Sidhu GS, Williamson EA, Jaiswal AS, Najmunnisa N, Wilcoxen K, et al. Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition. Cancer Chemother Pharmacol. 2017;80(4):861\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"44","key":"5314_CR12","doi-asserted-by":"publisher","first-page":"17079","DOI":"10.1073\/pnas.0806092105","volume":"105","author":"S Rottenberg","year":"2008","unstructured":"Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A. 2008;105(44):17079\u201384.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"5314_CR13","doi-asserted-by":"publisher","first-page":"6581","DOI":"10.1021\/jm8001263","volume":"51","author":"KA Menear","year":"2008","unstructured":"Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin- 1-one: a novel bioavailable inhibitor of poly (ADP-ribose) polymerase-1. J Med Chem. 2008;51(20):6581\u201391.","journal-title":"J Med Chem"},{"issue":"8","key":"5314_CR14","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jtho.2017.03.023","volume":"12","author":"R Parrotta","year":"2017","unstructured":"Parrotta R, Okonska A, Ronner M, Weder W, Stahel R, Penengo L, et al. A novel BRCA1-associated Protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair. J Thorac Oncol. 2017;12(8):1309\u201319.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"5314_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123\u201334.","journal-title":"N Engl J Med"},{"issue":"2","key":"5314_CR16","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jtho.2015.11.005","volume":"11","author":"F Galateau-Salle","year":"2016","unstructured":"Galateau-Salle F, Churg A, Roggli V, Travis WD. World Health Organization Committee for tumors of the P. The 2015 World Health Organization classification of tumors of the pleura: advances since the 2004 classification. J Thorac Oncol. 2016;11(2):142\u201354.","journal-title":"J Thorac Oncol"},{"issue":"2","key":"5314_CR17","first-page":"140","volume":"41","author":"S Patriarca","year":"2017","unstructured":"Patriarca S, Ferretti S, Zanetti R. TNM classification of malignant tumours - eighth edition: which news? Epidemiol Prev. 2017;41(2):140\u20133.","journal-title":"Epidemiol Prev"},{"issue":"2","key":"5314_CR18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1093\/annonc\/mdh059","volume":"15","author":"MJ Byrne","year":"2004","unstructured":"Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol. 2004;15(2):257\u201360.","journal-title":"Ann Oncol"},{"issue":"32","key":"5314_CR19","doi-asserted-by":"publisher","first-page":"22254","DOI":"10.18632\/oncotarget.24962","volume":"9","author":"FD Mairinger","year":"2018","unstructured":"Mairinger FD, Schmeller J, Borchert S, Wessolly M, Mairinger E, Kollmeier J, et al. Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy. Oncotarget. 2018;9(32):22254\u201368.","journal-title":"Oncotarget"},{"issue":"13","key":"5314_CR20","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.7150\/jca.16390","volume":"7","author":"RF Walter","year":"2016","unstructured":"Walter RF, Vollbrecht C, Werner R, Mairinger T, Schmeller J, Flom E, et al. Screening of pleural mesotheliomas for DNA-damage repair players by digital gene expression analysis can enhance clinical Management of Patients Receiving Platin-Based Chemotherapy. J Cancer. 2016;7(13):1915\u201325.","journal-title":"J Cancer"},{"key":"5314_CR21","doi-asserted-by":"publisher","first-page":"153303381881841","DOI":"10.1177\/1533033818818418","volume":"17","author":"M Wessolly","year":"2018","unstructured":"Wessolly M, Walter RFH, Vollbrecht C, Werner R, Borchert S, Schmeller J, et al. Processing escape mechanisms through altered proteasomal cleavage of epitopes affect immune response in pulmonary neuroendocrine tumors. Technol Cancer Res Treat. 2018;17:1533033818818418.","journal-title":"Technol Cancer Res Treat"},{"issue":"17","key":"5314_CR22","doi-asserted-by":"publisher","first-page":"4704","DOI":"10.1093\/emboj\/20.17.4704","volume":"20","author":"A Tutt","year":"2001","unstructured":"Tutt A, Bertwistle D, Valentine J, Gabriel A, Swift S, Ross G, et al. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J. 2001;20(17):4704\u201316.","journal-title":"EMBO J"},{"issue":"15","key":"5314_CR23","doi-asserted-by":"publisher","first-page":"8644","DOI":"10.1073\/pnas.151253498","volume":"98","author":"F Xia","year":"2001","unstructured":"Xia F, Taghian DG, DeFrank JS, Zeng ZC, Willers H, Iliakis G, et al. Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc Natl Acad Sci U S A. 2001;98(15):8644\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"5314_CR24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S1097-2765(01)00174-5","volume":"7","author":"ME Moynahan","year":"2001","unstructured":"Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell. 2001;7(2):263\u201372.","journal-title":"Mol Cell"},{"issue":"7381","key":"5314_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nature10760","volume":"481","author":"CJ Lord","year":"2012","unstructured":"Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature. 2012;481(7381):287\u201394.","journal-title":"Nature"},{"issue":"10","key":"5314_CR26","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/nrc1457","volume":"4","author":"N Turner","year":"2004","unstructured":"Turner N, Tutt A, Ashworth A. Hallmarks of \u2018BRCAness\u2019 in sporadic cancers. Nat Rev Cancer. 2004;4(10):814\u20139.","journal-title":"Nat Rev Cancer"},{"key":"5314_CR27","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2017.06.028","volume":"405","author":"M Betti","year":"2017","unstructured":"Betti M, Casalone E, Ferrante D, Aspesi A, Morleo G, Biasi A, et al. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma. Cancer Lett. 2017;405:38\u201345.","journal-title":"Cancer Lett"},{"issue":"43","key":"5314_CR28","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1038\/sj.onc.1204828","volume":"20","author":"A Rienzo De","year":"2001","unstructured":"De Rienzo A, Balsara BR, Apostolou S, Jhanwar SC, Testa JR. Loss of heterozygosity analysis defines a 3-cM region of 15q commonly deleted in human malignant mesothelioma. Oncogene. 2001;20(43):6245\u20139.","journal-title":"Oncogene"},{"issue":"7","key":"5314_CR29","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.dnarep.2007.02.002","volume":"6","author":"KJ Patel","year":"2007","unstructured":"Patel KJ, Joenje H. Fanconi anemia and DNA replication repair. DNA Repair (Amst). 2007;6(7):885\u201390.","journal-title":"DNA Repair (Amst)"},{"issue":"1","key":"5314_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrc970","volume":"3","author":"AD D'Andrea","year":"2003","unstructured":"D'Andrea AD, Grompe M. The Fanconi anaemia\/BRCA pathway. Nat Rev Cancer. 2003;3(1):23\u201334.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"5314_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.lungcan.2009.03.016","volume":"67","author":"OD Roe","year":"2010","unstructured":"Roe OD, Anderssen E, Sandeck H, Christensen T, Larsson E, Lundgren S. Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets. Lung Cancer. 2010;67(1):57\u201368.","journal-title":"Lung Cancer"},{"issue":"3","key":"5314_CR32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/pcan.2013.12","volume":"16","author":"P Luca De","year":"2013","unstructured":"De Luca P, Moiola CP, Zalazar F, Gardner K, Vazquez ES, De Siervi A. BRCA1 and p53 regulate critical prostate cancer pathways. Prostate Cancer Prostatic Dis. 2013;16(3):233\u20138.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"5314_CR33","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/ijc.25112","volume":"127","author":"BM Barakat","year":"2010","unstructured":"Barakat BM, Wang QE, Han C, Milum K, Yin DT, Zhao Q, et al. Overexpression of DDB2 enhances the sensitivity of human ovarian cancer cells to cisplatin by augmenting cellular apoptosis. Int J Cancer. 2010;127(4):977\u201388.","journal-title":"Int J Cancer"},{"issue":"1","key":"5314_CR34","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ygyno.2016.01.004","volume":"141","author":"M Zhang","year":"2016","unstructured":"Zhang M, Liu G, Xue F, Edwards R, Sood AK, Zhang W, et al. Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer. Gynecol Oncol. 2016;141(1):57\u201364.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"5314_CR35","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","volume":"43","author":"M Bott","year":"2011","unstructured":"Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668\u201372.","journal-title":"Nat Genet"},{"issue":"10","key":"5314_CR36","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","volume":"43","author":"JR Testa","year":"2011","unstructured":"Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet. 2011;43(10):1022\u20135.","journal-title":"Nat Genet"},{"issue":"11","key":"5314_CR37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.21037\/atm.2017.04.06","volume":"5","author":"SA Emri","year":"2017","unstructured":"Emri SA. The Cappadocia mesothelioma epidemic: its influence in Turkey and abroad. Ann Transl Med. 2017;5(11):239.","journal-title":"Ann Transl Med."},{"issue":"3","key":"5314_CR38","doi-asserted-by":"publisher","first-page":"248","DOI":"10.21037\/tlcr.2017.04.12","volume":"6","author":"A Singh","year":"2017","unstructured":"Singh A, Pruett N, Hoang CD. In vitro experimental models of mesothelioma revisited. Transl Lung Cancer Res. 2017;6(3):248\u201358.","journal-title":"Transl Lung Cancer Res"},{"issue":"5","key":"5314_CR39","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1165\/rcmb.2010-0282OC","volume":"45","author":"A Shukla","year":"2011","unstructured":"Shukla A, Barrett TF, MacPherson MB, Hillegass JM, Fukagawa NK, Swain WA, et al. An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury. Am J Respir Cell Mol Biol. 2011;45(5):906\u201314.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"5314_CR40","unstructured":"Database GHG. www.genecards.org . Accessed 20 June 2018."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5314-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5314-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5314-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T12:25:19Z","timestamp":1720959919000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5314-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,30]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5314"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5314-0","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,30]]},"assertion":[{"value":"2 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study conforms to the principles outlined in the declaration of Helsinki and was approved by the institutional review board (Ethics Committee of the Medical Faculty of the University Duisburg-Essen), protocol no.: 14\u20135775-BO. Due to the ethics approval, a patients\u2019 informed consent has not been obtained.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have read and approved the manuscript and are aware of the submission. The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"108"}}